Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

News from the Trials

Keep up to date with latest news and analyses from PCSK9 inhibitor trials.

View latest news »

Trial Resources

For expert analysis and insights

View Trials »

View Trial slide decks »

From the Editors

MK-0616 - How near is an oral PCSK9i?

John chapman & Chris PackardProfessors John Chapman and Chris Packard consider the evidence supporting MK-0616 as potentially the first oral PCSK9i to reach the clinic.

Read the editorial

Related reports:

Phase 2b data show benefits of oral MK-0616 in hypercholesterolaemia

MK-0616: Hope for an oral PCSK9 inhibitor?

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower LDL-C, which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature CV death and disability.
Read more »

Increasing awareness, knowledge and understanding of elevated serum TGs in the development of CVD and pancreatitis and stimulating research of novel therapeutic strategies.


Meet our Editorial Board

View all our Editorial Board Prof John ChapmanResearch Professor at the Sorbonne University Prof Henry GinsbergIrving Professor of Medicine, Columbia University Dr Michel FarnierClinician based at Point Medical, Dijon, France Prof Frederick RaalDirector, Carbohydrate & Lipid Metabolism Research Unit Prof Anthony WierzbickiConsultant in Metabolic Medicine/Chemical Pathology